For example, in CRC, Talazoparib leads to p21 activation, stimulates inducing cellular senescence (TIS), and thus activates the cGAS-STING pathway, promotes the secretion of type I interferon (IFN-I) and stimulates anti-tumor immune responses by blocking ubiquitination of p53. Here, CGAS is linked to colorectal carcinoma.